Organizing care for cystic fibrosis patients using new treatments
Official title: Rethinking CF Organization of Care in the Era of Highly Effective Modulator: a Nationwide Research Program HORIZON.
Run by Hospices Civils de Lyon · NCT06599892 · Data updated 2026-11-12
This study looks at how new cystic fibrosis treatments are changing the way care is organized and delivered to patients in France.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 6 Years and up |
| Sex | All |
| Enrollment | 5000 (estimated) |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Lyon) |
| Status | Recruiting |
| Started | September 1, 2023 |
| Main results expected | December 31, 2026 |
| Study ends | June 30, 2027 |
| Registry record updated | September 19, 2024 |
| Trial ID | NCT06599892 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients aged 6 and over with cystic fibrosis who have been treated with CFTR modulators for at least 12 months, as well as those not eligible for such treatment.
✕Probably not a fit
Patients who refuse to participate or those under legal protection or psychiatric care may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study examines how the introduction of highly effective CFTR modulators has transformed the management of cystic fibrosis in France. It focuses on the organization of care provided by cystic fibrosis resource and competence centers (CRCMs), which offer multidisciplinary support to patients. The study aims to redefine the roles of healthcare professionals and the patient-professional relationship in light of these new treatment options. By analyzing the experiences of patients and healthcare providers, the study seeks to improve care pathways and outcomes for cystic fibrosis patients.
Why it matters
Potential benefit: If successful, this study could lead to improved care coordination and better health outcomes for cystic fibrosis patients.
How similar studies have gone: Other studies have shown positive outcomes with similar approaches in managing cystic fibrosis care, particularly with the introduction of new therapies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 6 and over with cystic fibrosis treated with CFTRmHE for at least 12 months * Patients aged over 6 years with cystic fibrosis not eligible for CFTRmHE treatment * Families of patients under 18 years of age * Professionals working in a CRCM for more than 12 months, physiotherapists and community nurses involved in the management of cystic fibrosis. Exclusion Criteria \* : * Refusal to participate * Persons deprived of their liberty by judicial or administrative decision * Persons under psychiatric care * Adults under legal protection (guardianship, curatorship) * Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
Where it's running
-
Groupement Hospitalier Est Pediatric CFcenter
Lyon, France Recruiting
Study contacts
- Principal investigator: Philippe REIX, Professor — Hospices Civils de Lyon
- Study coordinator: Philippe REIX, Professor
- Email: philippe.reix@chu-lyon.fr
- Phone: 04 27 85 50 42
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Inhaled CFTR mRNA for cystic fibrosis in Chinese patients aged 12 and older
This trial tests inhaled BMD003, a CFTR mRNA therapy, to see if it's safe and shows early signs of benefit in Chinese people 12 years and up with cystic fibrosis.
-
VX-272 dose escalation in healthy adults
This will test single and multiple increasing doses of the experimental drug VX-272 in healthy adults to see how safe it is and how the body handles it.
-
Prevalence of smoking, passive smoke exposure, and vaping among adults with cystic fibrosis
This project will see how common smoking, exposure to secondhand smoke, and vaping are among adults with cystic fibrosis followed at the Strasbourg Adult CF Center.
-
Dose escalation of VX-581 to check safety and drug levels in healthy adults
The trial will test increasing doses of VX-581 in healthy adults to see if it is safe and to measure how the body absorbs and clears the drug.
-
PALMIRE cohort: phenotyping inflammatory lung diseases to enable personalized care
This project will collect clinical, imaging, and biological data from adults with asthma, COPD, bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, or interstitial lung disease to try to identify disease subtypes and markers that could guide more personalized care.
-
Collecting sputum samples at home for cystic fibrosis patients
This study is testing if collecting sputum samples at home can help people with cystic fibrosis better identify lung infections compared to traditional methods done at the clinic.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.